Review Article
New Molecular Targeted Therapy and Redifferentiation Therapy for Radioiodine-Refractory Advanced Papillary Thyroid Carcinoma: Literature Review
Table 2
Study on target therapy in radioiodine-refractory papillary thyroid cancer.
| | Author | Study | Agent | Number of patients [type] | Result | | | | | | Response rate
(%) | Stabilization
(%) | Progression-free survival
(months) | Discontinuation due to adverse effect |
| | Gupta-Abramson et al. [19] | Phase II | Sorafenib | 30 [DTC and MTC]
(i) DTC: 27/30
(ii) PTC: 18/30 | 23%
25.9%
22.2% | 53%
55.6%
61.1% | 18.2 (79 weeks)
19.3 (84 weeks) | 16.7% |
| | Kloos et al. [20] | Phase II | Sorafenib | 41 [PTC] | 15% | 56% (≥6 months) | 15 | — |
| | Hoftijzer et al. [21] | Phase II | Sorafenib | 31 [DTC]
PTC: 14/31 | 25% | 34% (26 weeks) | 13.3 (58 weeks) | 19.4% |
| | Chen et al. [22] | Phase II | Sorafenib | 9 [PTC] | 33% | 44% | 9.6 (42 weeks) | 0 |
| | Ahmed et al. [23] | Phase II | Sorafenib | 34 [MTC and DTC]
PTC: 19/34 | 15%
18% | 74% (6 months) | — | 5.9% |
| | Capdevila et al. [24] | Phase II | Sorafenib | 34**
(i) DTC: 16/34
(ii) PTC: 7/34 | 32%
19%
14% | 41% (6 months)
50%
43% | 13.5 | — |
| | Cohen et al. [25] | Phase II | Axitinib | 60 [DTC]
PTC: 30/60 | 30%
26.7% | 38% (≥16 weeks)
40% | 18.1 | 13% |
| | Sherman et al. [26] | Phase II | Motesanib | 93 [DTC]
PTC: 57/93 | 14% | 35% (24 weeks) | 9.3 | 13% |
| | Carr et al. [27] | Phase II | Sunitinib | 35 [DTC and MTC]
(i) DTC: 28/35
(ii) PTC: 18/35 | 31%
28% | 46%
68% | 12.8 | 11.4% |
| | Cohen et al. [28] | Phase II | Sunitinib | 31 [DTC] | 13% | 68% | — | — |
| | Bible et al. [29] | Phase II | Pazopanib | 37 [DTC]
PTC: 15/37 | 49%
33% | — | 11.7 | 5.4% |
| | Sherman et al. [30] | Phase II | Lenvatinib | 58 [DTC]
PTC: 43/58 | 50% | 36% | 13.3 | 23% |
| | Cabanillas et al. [31] | Phase II | Cabozantinib | 15 [DTC] | 53% | 40% | — | — |
| | Leboulleux et al. [32] | RCT, phase II | Vandetanib | 72 versus 73 [DTC]
PTC: 25 versus 24 | 8.3% versus 5.5% | 56% versus 36%* | 11.1 versus 5.8*
16.2 versus 5.9 | 33% versus 6% |
| | Pennell et al. [33] | Phase II | Gefitinib | 27**
PTC: 11/27 | 0% | 24% (6 months) | 3.7 | 7.4% |
| | Hayes et al. [34] | Phase II | Selumetinib | 32 [PTC] | 3% | 36% (24 weeks) | 7.4 | — |
| | Falchook et al. [35] | Phase I | Dabrafenib | 14 [PTC] | 21.4% | — | — | 0 |
|
|
DTC: differentiated thyroid cancer, PTC: papillary thyroid cancer, MTC: medullary thyroid cancer; RCT: randomized controlled trial.
*
.
**Included differentiated, medullary, and anaplastic thyroid carcinoma.
|
